טוען...
Canadian cohort expanded-access program of nivolumab plus ipilimumab in advanced melanoma
BACKGROUND: The combination of nivolumab and ipilimumab is approved in several jurisdictions (United States, European Union, Canada) for the first-line treatment of patients with advanced melanoma. CheckMate 218 is a North American expanded-access program (eap) of nivolumab plus ipilimumab in patien...
שמור ב:
| הוצא לאור ב: | Curr Oncol |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Multimed Inc.
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7467793/ https://ncbi.nlm.nih.gov/pubmed/32905202 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.27.5985 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|